title: Effective regional therapy of experimental cancer with paralesional administration of tumour necrosis factor-alpha + interferon-gamma.
abstract: Systemically administered tumour necrosis factor (TNF) has anti-tumour effects in animal tumour models but its clinical application is limited by severe toxicity. Interferon-gamma(IFN-gamma) has been shown to augment the anti-tumour effect of TNF. We evaluated the effect of paralesional (p.I.) injections of TNF plus IFN-gamma in a murine tumour model and compared the toxicity and anti-tumour effect with that seen with systemic administration. C57BL6 mice with 10-day subcutaneous MCA sarcomas were treated with daily p.I. injections of recombinant huTNF +/- IFN-gamma for 5 days. Optimal mean survival and 30-day cure rate was seen with doses of 5 micrograms TNF-alpha + 5000 U IFN-gamma (P < 0.05 vs. control or IFN-gamma alone). Tumour response after a single i.v. injection of 0-15 micrograms TNF + 5000 U IFN-gamma was then compared with five daily p.I. injections of the same dose of TNF-alpha and IFN-gamma. All animals with p.I. injections of > 5 micrograms TNF had initial complete necrosis of tumour with a variable degree of surrounding tissue necrosis, with rapid regrowth of tumour seen in some animals. Although treatment-related mortality was similar between i.v. and p.I. therapy, there was a higher percentage of animals cured with p.I. injections with overall cure rates in treated animals at 30 days of 17% vs. 72% (i.v. vs. p.I., P < 0.01) and 13% vs. 67% (P < 0.04) in a repeat study. 2+ clinical applications.
authors.affiliation: Surgical Metabolism Section, National Cancer Institute, National Institutes of Health, Bethesda, MD.
authors.forename: A K
authors.initials: AK
authors.lastname: Thom
authors.forename: D L
authors.initials: DL
authors.lastname: Fraker
authors.forename: J K
authors.initials: JK
authors.lastname: Taubenberger
authors.forename: J A
authors.initials: JA
authors.lastname: Norton
mesh_terms: D000818:Animals; D004354:Drug Screening Assays, Antitumor; D004357:Drug Synergism; D005260:Female; D015552:Injections, Intralesional; D007371:Interferon-gamma / Q000008:administration & dosage* / Q000633:toxicity; D008748:Methylcholanthrene; D051379:Mice; D008810:Mice, Inbred C57BL; D009368:Neoplasm Transplantation; D011897:Random Allocation; D011994:Recombinant Proteins; D012074:Remission Induction; D012513:Sarcoma, Experimental / Q000139:chemically induced / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D014409:Tumor Necrosis Factor-alpha / Q000008:administration & dosage* / Q000633:toxicity
chemical_list: D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha; D008748:Methylcholanthrene; D007371:Interferon-gamma